

Sample Nr. 210082196 Manufacturing Date 07/04/2017 Retest Date 07/04/2022

Code Lot/Batch Description Product Class
G1MR 0000255076 DALFAMPRIDINE MICRONIZED FERT CLASSE A

Tests	Results	Units	Specification
CHARACTERS			
APPEARANCE	Complies to specification	-	White to off-white powder
C-USP<197> - C-EP 2.2.24.			
IR IDENTIFICATION	Complies to specification	-	Complies with Ref.STD
IDENTIFICATION HPLC G1T			
RETENTION TIME	Complies to specification	-	Complies with Ref.STD
RELATED SUBSTANCES HPLC G1			
2-Aminopyridine	Not Detected	%	NMT 0.1%
Isonicotinic Acid	<0.02	%	NMT 0.1%
Each unknown impurity	<0.02	%	NMT 0.10%
Total impurities	0.00	%	NMT 0.5%
RELATED SUBSTANCES UPLC-MS G1			
3-Aminopyridine	Not Detected	-	NMT 75 ppm
Dalfampridine Dimer	Not Detected	-	NMT 75 ppm
Isonicotinamide	Complies to specification	-	NMT 75 ppm
Dalfampridine n-oxide	Complies to specification	-	NMT 75 ppm
ASSAY HPLC G1T			
ASSAY (Anhydrous and solvent free basis)	100.1	%	Between 98.0% and 102.0%
C-USP <921> METHOD I - C-EP 2.5.12.			
WATER	0.03	%	NMT 0.5%
RESIDUAL SOLVENTS GC G1SR			
Acetone	<160	ppm	NMT 5000 ppm
Isobutyl alcohol	Not Detected	ppm	NMT 5000 ppm
MIBK	Not Detected	ppm	NMT 4500 ppm
Total residual solvents	0	ppm	NMT 5000 ppm
C-USP<281> - C-EP 2.4.14.			
RESIDUE ON IGNITION/SULPHATED ASH	0.01	%	NMT 0.1%
C-USP<231>METHOD II - C-EP 2.4.8.			
HEAVY METALS	Complies to specification	-	NMT 10 ppm

Sample Nr. 210082196 Manufacturing Date 07/04/2017 Retest Date 07/04/2022

Code	Lot/Batch	Description	Product Class
G1MR	0000255076	DALFAMPRIDINE MICRONIZED	FERT CLASSE A

Tests	Results	Units	Specification
C-USP<941> - C-EP 2.9.33. (X-RAY DIFFR)			
Crystallinity	Complies to specification	-	Complies with Ref.STD

Notes

FERT Pharmaceutical Active Ingredient
PROCOS CLASS PRODUCT COMPLIES WITH PROCOS SPECIFICATIONS

Lot Released : Complies with all specifications of the testing instruction and with GMP standard.

Cameri, February 20, 2019
Procos Spa
Quality Control

Authorized Person

TIZIANO RUFFILLI

Tiziano Ruffilli

A.C.E.F. S.p.A